Popular Locations
- Smilow Cancer Hospital
- Smilow Cancer Hospital Care Center - North Haven
- Smilow Cancer Hospital Care Center - Park Avenue Medical Center
Cell-based gene therapy is an innovative treatment for people who are diagnosed with certain genetic blood disorders. Cell-based gene therapy uses a patient’s own stem cells, which are collected and then modified in a manufacturing facility. The goal of gene therapy is to treat the disease at the genetic level by either adding new genes (gene addition) or editing existing genes. Once manufacturing is complete, the patient receives chemotherapy, and the modified cells are returned to the patient, where they can help produce healthier blood cells over time. Gene therapy represents a significant advancement in care, with the potential for long-term improvement in quality of life.
We offer FDA-approved gene therapies, each designed for specific inherited blood disorders, sickle cell disease and transfusion dependent beta thalassemia. While the details differ between therapies, the overall goal is similar: to reduce or eliminate the need for chronic treatments by enabling the body to produce healthier cells on its own.
A successful gene therapy journey requires close collaboration between patients, caregivers, and the healthcare team. Before treatment begins, patients identify a dedicated live-in caregiver, typically a family member or close friend, who will provide essential support throughout treatment and recovery. Patients receiving gene therapy often remain hospitalized for approximately four to six weeks, although the exact duration varies depending on individual circumstances. After discharge, ongoing follow-up care is critical to monitor recovery, assess how well the gene-modified stem cells are functioning, and identify any potential complications.
At Smilow Cancer Hospital we remain committed to our patients long after treatment is complete, providing expert care and lifelong partnership throughout their journey.
When Marc St. Martin was diagnosed with cutaneous T-cell lymphoma (CTCL) in 2007, he had no way of knowing the impact it would have throughout his family. Over the course of five years, Marc underwent treatment with spot radiation therapy, total skin electron beam therapy, and chemotherapy, all in the hopes of achieving a durable remission.
Read MoreYale New Haven Health is proud to be affiliated with the prestigious Yale University and its highly ranked Yale School of Medicine.